154 related articles for article (PubMed ID: 17402834)
1. Faropenem: review of a new oral penem.
Schurek KN; Wiebe R; Karlowsky JA; Rubinstein E; Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):185-98. PubMed ID: 17402834
[TBL] [Abstract][Full Text] [Related]
2. Faropenem medoxomil.
Gettig JP; Crank CW; Philbrick AH
Ann Pharmacother; 2008 Jan; 42(1):80-90. PubMed ID: 18094341
[TBL] [Abstract][Full Text] [Related]
3. Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026.
Drugs R D; 2008; 9(2):115-24. PubMed ID: 18298129
[TBL] [Abstract][Full Text] [Related]
4. Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.
Hadley JA; Tillotson GS; Tosiello R; Echols RM
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):923-37. PubMed ID: 17181408
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis.
Upchurch J; Rosemore M; Tosiello R; Kowalsky S; Echols R
Otolaryngol Head Neck Surg; 2006 Oct; 135(4):511-7. PubMed ID: 17011409
[TBL] [Abstract][Full Text] [Related]
6. Appropriate prescribing of oral beta-lactam antibiotics.
Holten KB; Onusko EM
Am Fam Physician; 2000 Aug; 62(3):611-20. PubMed ID: 10950216
[TBL] [Abstract][Full Text] [Related]
7. Oral beta-lactams applied to uncomplicated infections of skin and skin structures.
Jacobs MR; Jones RN; Giordano PA
Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):55S-65S. PubMed ID: 17292581
[TBL] [Abstract][Full Text] [Related]
8. Redefining penems.
Dalhoff A; Janjic N; Echols R
Biochem Pharmacol; 2006 Mar; 71(7):1085-95. PubMed ID: 16413506
[TBL] [Abstract][Full Text] [Related]
9. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
[TBL] [Abstract][Full Text] [Related]
10. Carbapenems: a potent class of antibiotics.
Nicolau DP
Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
[TBL] [Abstract][Full Text] [Related]
11. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
Matthews SJ; Lancaster JW
Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
[TBL] [Abstract][Full Text] [Related]
12. Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis.
Anzueto A; Bishai WR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):31S-38S. PubMed ID: 17349461
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of faropenem against staphylococci.
von Eiff C; Schepers S; Peters G
J Antimicrob Chemother; 2002 Aug; 50(2):277-80. PubMed ID: 12161412
[TBL] [Abstract][Full Text] [Related]
15. Oral beta-lactams in the treatment of acute bacterial rhinosinusitis.
Hadley JA; Pfaller MA
Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):47S-54S. PubMed ID: 17292580
[TBL] [Abstract][Full Text] [Related]
16. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute uncomplicated cystitis with faropenem for 3 days versus 7 days: multicentre, randomized, open-label, controlled trial.
Hamasuna R; Tanaka K; Hayami H; Yasuda M; Takahashi S; Kobayashi K; Kiyota H; Yamamoto S; Arakawa S; Matsumoto T;
J Antimicrob Chemother; 2014 Jun; 69(6):1675-80. PubMed ID: 24508899
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
19. The challenge of multidrug resistance: the treatment of gram-negative rod infections.
Levin AS; Oliveira MS
Shock; 2008 Oct; 30 Suppl 1():30-3. PubMed ID: 18704012
[TBL] [Abstract][Full Text] [Related]
20. The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections.
Ball P
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S113-7. PubMed ID: 17997283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
